Follicular lymphoma: To treat or not to treat is no longer the question

Journal of the National Cancer Institute

Volumn 104, Issue 1, 2012, Pages 3-5

  Jacobson, Caron A ^a   Longo, Dan L ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); METASTASIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, FOLLICULAR; STEM CELL TRANSPLANTATION;

EID: 84855502937     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr498     Document Type: Editorial

References (25)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909-3918.
2. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019-5026. (Pubitemid 46224008)
3. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522. (Pubitemid 36976715)
4. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2)(suppl 2):11-16.
5. Ardeshna K, Smith P, Qian W, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a). A preliminary analysis. Blood. 2010;116. Abstract 6.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732. (Pubitemid 41742196)
7. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorabucil, and prednisone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-1992. (Pubitemid 46972781)
8. Marcus R, Imrie K, Solal-Celigny P, et al. Phase II study of R-CVP compared with cyclophosphamide, vincristine, prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
9. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in folliculuar lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-4831.
10. Hockster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607-1614.
11. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
12. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(9):2667-2674. (Pubitemid 39434946)
13. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multi-center study by GOELAMS. Blood. 2005;105(10):3817-3823. (Pubitemid 40656123)
14. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Group d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;108(8):2540-2544.
15. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-4013.
16. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;104(1):18-28.
17. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995-1001.
18. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(10):2208-2214. (Pubitemid 46218712)
19. Brown JR, Feng Y, Gribben JG, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13(9):1057-1065. (Pubitemid 47224617)
20. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918-3927. (Pubitemid 46606204)
21. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25(18):2554-2559. (Pubitemid 47044812)
22. Le Gouill S, De Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematol. 2011;96(8):1128-1135.
23. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614-3620.
24. Weigert O, Uysal A, Metzner B, et al. Impact of autologous stem cell transplantation and/or rituximab in patients with relapsed follicular lymphoma - a retrospective analysis of 2 randomized trials for the German Low Grade Lymphoma Study Group (GLSG). Blood. 2008;114(suppl 1). Abstract 2189.
25. Seyfarth B, Kuse R, Sonnen R, et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol. 2001;80(7):398-405. (Pubitemid 32725457)